Biogen Inc. vs Merck & Company, Inc. — Stock Comparison
Q·Score Breakdown
7.5
Buy
Overall
7.3
Buy
Quality
Health
Growth
Valuation
Sentiment
BIIB
Clean balance sheet with low leverage (0.4× debt-to-equity).
MRK
High-quality business with 37% return on equity and 28% profit margins.
⚠ earnings contracting 19% year-over-year.
Analyst Consensus
BUY
Target $212.51 (+10.8%)
29 analysts
BUY
Target $129.74 (+17.3%)
27 analysts
Fundamentals
BIIB
MRK
20.7×
Trailing P/E
15.2×
12.0×
Forward P/E
11.4×
13.8%
Profit Margin
28.1%
78.7%
Gross Margin
77.2%
7.7%
ROE
36.9%
1.9%
Revenue Growth
5.0%
31.1%
Earnings Growth
-19.3%
0.16
Beta
0.28
—
Price / Book
—
$28.3B
Market Cap
$273.1B
$115 – $202
52-Week Range
$73 – $125
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load.